BioRestorative Therapies annual operating margin
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BioRestorative Therapies's operating margin was −4,350.05% for fiscal 2025.
View full BioRestorative Therapies company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −4,350.05% | −1468.46 pp |
| 2024 | 2024-12-31 | −2,881.59% | +7557.89 pp |
| 2023 | 2023-12-31 | −10,439.49% | +5398.60 pp |
| 2022 | 2022-12-31 | −15,838.08% | +41352.94 pp |
| 2021 | 2021-12-31 | −57,191.03% | −53616.90 pp |
| 2020 | 2020-12-31 | −3,574.12% | +2912.03 pp |
| 2019 | 2019-12-31 | −6,486.16% | +403.62 pp |
| 2018 | 2018-12-31 | −6,889.78% | +3448.85 pp |
| 2017 | 2017-12-31 | −10,338.62% | +11075.42 pp |
| 2016 | 2016-12-31 | −21,414.04% | −20273.93 pp |
| 2015 | 2015-12-31 | −1,140.12% | +43.19 pp |
| 2014 | 2014-12-31 | −1,183.31% | +281689.91 pp |
| 2013 | 2013-12-31 | −282,873.21% | −247127.16 pp |
| 2012 | 2012-12-31 | −35,746.05% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −14,612.57% | +4617.56 pp |
| Q4 2025 | 2025-12-31 | −19,516.84% | −13304.04 pp |
| Q3 2025 | 2025-09-30 | −31,432.30% | −30453.28 pp |
| Q2 2025 | 2025-06-30 | −1,089.77% | +1681.05 pp |
| Q1 2025 | 2025-03-31 | −19,230.14% | −7489.42 pp |
| Q4 2024 | 2024-12-31 | −6,212.80% | +10474.67 pp |
| Q3 2024 | 2024-09-30 | −979.02% | +9133.17 pp |
| Q2 2024 | 2024-06-30 | −2,770.83% | +2061.03 pp |
| Q1 2024 | 2024-03-31 | −11,740.72% | +6722.85 pp |
| Q4 2023 | 2023-12-31 | −16,687.47% | +109850.47 pp |
| Q3 2023 | 2023-09-30 | −10,112.19% | +5783.33 pp |
| Q2 2023 | 2023-06-30 | −4,831.86% | +1678.16 pp |
| Q1 2023 | 2023-03-31 | −18,463.57% | +13122.63 pp |
| Q4 2022 | 2022-12-31 | −126,537.95% | −46352.61 pp |
| Q3 2022 | 2022-09-30 | −15,895.52% | +30213.07 pp |
| Q2 2022 | 2022-06-30 | −6,510.03% | +17191.73 pp |
| Q1 2022 | 2022-03-31 | −31,586.21% | +52050.77 pp |
| Q4 2021 | 2021-12-31 | −80,185.34% | −75119.26 pp |
| Q3 2021 | 2021-09-30 | −46,108.59% | −42040.15 pp |
| Q2 2021 | 2021-06-30 | −23,701.75% | −21272.34 pp |
| Q1 2021 | 2021-03-31 | −83,636.98% | −80487.02 pp |
| Q4 2020 | 2020-12-31 | −5,066.08% | +1671.01 pp |
| Q3 2020 | 2020-09-30 | −4,068.43% | +718.40 pp |
| Q2 2020 | 2020-06-30 | −2,429.41% | +4437.70 pp |
| Q1 2020 | 2020-03-31 | −3,149.96% | +4878.79 pp |
| Q4 2019 | 2019-12-31 | −6,737.09% | +772.94 pp |
| Q3 2019 | 2019-09-30 | −4,786.83% | −215.02 pp |
| Q2 2019 | 2019-06-30 | −6,867.11% | −1325.66 pp |
| Q1 2019 | 2019-03-31 | −8,028.74% | +3711.98 pp |
| Q4 2018 | 2018-12-31 | −7,510.03% | −3372.50 pp |
| Q3 2018 | 2018-09-30 | −4,571.81% | +6325.92 pp |
| Q2 2018 | 2018-06-30 | −5,541.45% | +7303.63 pp |
| Q1 2018 | 2018-03-31 | −11,740.73% | +23821.72 pp |
| Q4 2017 | 2017-12-31 | −4,137.53% | +26472.89 pp |
| Q3 2017 | 2017-09-30 | −10,897.73% | +23406.51 pp |
| Q2 2017 | 2017-06-30 | −12,845.08% | +421.07 pp |
| Q1 2017 | 2017-03-31 | −35,562.44% | −12908.92 pp |
| Q4 2016 | 2016-12-31 | −30,610.42% | −29208.46 pp |
| Q3 2016 | 2016-09-30 | −34,304.24% | −32754.22 pp |
| Q2 2016 | 2016-06-30 | −13,266.15% | −12417.28 pp |
| Q1 2016 | 2016-03-31 | −22,653.52% | −21774.16 pp |
| Q4 2015 | 2015-12-31 | −1,401.96% | +248.94 pp |
| Q3 2015 | 2015-09-30 | −1,550.02% | −989.77 pp |
| Q2 2015 | 2015-06-30 | −848.86% | −120.50 pp |
| Q1 2015 | 2015-03-31 | −879.37% | +380032.10 pp |
| Q4 2014 | 2014-12-31 | −1,650.90% | +901550.70 pp |
| Q3 2014 | 2014-09-30 | −560.25% | +261528.69 pp |
| Q2 2014 | 2014-06-30 | −728.36% | +114278.81 pp |
| Q1 2014 | 2014-03-31 | −380,911.47% | +87177.82 pp |
| Q3 2013 | 2013-09-30 | −903,201.60% | −880135.92 pp |
| Q2 2013 | 2013-06-30 | −262,088.94% | −248696.94 pp |
| Q1 2013 | 2013-03-31 | −115,007.17% | — |
| Q4 2012 | 2012-12-31 | −468,089.29% | — |
| Q3 2012 | 2012-09-30 | −23,065.68% | — |
| Q2 2012 | 2012-06-30 | −13,392.00% | — |
Over the last five reported fiscal years, BioRestorative Therapies's operating margin decreased from −3,574.12% to −4,350.05%, a change of −775.93 percentage points. The latest reported quarter, Q1 2026, shows −14,612.57%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioRestorative Therapies filings at SEC.gov ↗